Curriculum Vitae

Panos Zanos, Ph.D. Assistant Professor, Department of Psychiatry, University of Maryland, School of Medicine

Date September 27, 2019

Contact Information

Business Address: 685 West Baltimore Street, Baltimore, Maryland, 21209, USA Email: [email protected] Foreign Languages: Greek (native), French (working knowledge)

Education

2007 - 2010 BSc (Hons) Biochemistry, University of Surrey, Guildford University of Surrey, Guildford, Surrey, U.K. Final year project: The role of regulatory appetite peptides in drug addiction.

2010 - 2013 Ph.D. in Neuropharmacology University of Surrey, Guildford, Surrey, U.K. Supervised by Prof. Ian Kitchen, Dr. Alexis Bailey and Dr. Raphaelle Winsky-Sommerer Title of thesis: The role of oxytocin in drug addiction and relapse

Post Graduate Education and Training

2013 - 2018 Post-doctoral Research Fellow University of Maryland, School of Medicine, Department of Psychiatry, Baltimore, SupervisedU.S.A. by Dr. Todd Gould

Academic Appointments

Nov 2018 – Instructor, University of Maryland, School of Medicine, Department of Aug 2019 Psychiatry, Baltimore, U.S.A.

Aug 2019 – Assistant Professor, non-tenured track, University of Maryland, School of Medicine, Department of Psychiatry, Baltimore, U.S.A.

Professional Society Memberships

1. Society of Neuroscience (4 years; postdoctoral membership – current) 2. International Behavioral Neuroscience Society (2 year; postdoctoral membership – current) 3. Society of Biology (1 year; undergraduate membership – past) 4. British Pharmacological Society (3 years; undergraduate membership – past)

Honors and Awards

2007 Scholarship for academic excellence – University of Surrey, U.K. 2008 Scholarship for academic excellence – University of Surrey, U.K. 2009 Scholarship for academic excellence – University of Surrey, U.K. 2010 University of Surrey Award – BSc Biochemistry award for academic excellence 2011 Travel award to attend European Opioid Conference (Krakow, Poland) 2011 Scholarship to attend Neuroscience School of Advanced Studies (Siena, Italy) 2012 Best Oral Communication (FHMS festival of Research – University of Surrey, Guildford) 2013 Best poster presentation prize, European opioid conference, Guildford, U.K. 2013 Ruth Humphrey Fund to attend World Congress of Neurohypophysial Hormones (Bristol, U.K.) 2013 Award for best inter-faculty Ph.D. student of the University of Surrey, Guildford, U.K. 2014 Best Poster Presentation award (Department of Psychiatry, University of Maryland, Baltimore) 2016 Best mentor award (Program in Neuroscience, University of Maryland, Baltimore; selected by students, peers and faculty) 2016 University of Maryland, Baltimore, Postdoctoral Travel Award (based on outstanding research achievements) to attend the Society for Neuroscience, SfN meeting in San Diego, CA, U.S.A. 2017 Society of Biological Psychiatry Travel Fellowship Award to attend the SOBP 2017 meeting in San Diego, CA, U.S.A. 2017 Best Postdoctoral Scholar awardee, University of Maryland, School of Medicine 2018 Travel award to attend the 2018 ACNP Annual Meeting, FL, U.S.A.

Teaching Service

2010-2013 Lecturing Undergraduate Students on Biology at the University of Surrey; Teaching Assistant: Pharmacology, Biochemistry; Teaching Addiction Neuropharmacology to A- level Summer school students; University of Surrey, UK. 2017-present Visiting Lecturer St. Elizabeth’s Hospital; Lectures on “Mechanisms of action of novel fast-acting antidepressants”, to Psychiatrist Residents

Grant Support

Active Grants

01/15/18 - 01/14/2020 (Principal Investigator) “Effects of ketamine’s metabolite (2R,6R)-HNK on opioid withdrawal- induced emotional impairment and drug-seeking reinstatement” NARSAD Young Investigator Grant

Completed Grants

01/01/17 - 12/31/2018 (Co-Investigator) “AMPAR mechanism of ketamine antidepressant action: validation” NIH Bench to Bedside Award

Patents, Inventions and Copyrights

1. WO/2017/165877. Methods of using (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, ahedonia, suicidal ideation, and post-traumatic stress disorder. (Co- inventor). 2. WO/2017/165878. Crystal forms and methods of synthesis of (2R,6R)-hydroxynorketamine and (2S,6S)- hydroxynorketamine. (Co-inventor).

Publications

Peer-reviewed journal articles

1. Fragou, D., Zanos, P., Kouidou, S., Njau, S., Kitchen, I., Bailey, A., Kovatsi, L. Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver. Toxicology letters, 2013, 218, 260-5. 2. Zanos, P., Georgiou, P., Wright, R.S., Kitchen, I., Winsky-Sommerer, R., Bailey, A. The oxytocin analogue carbetocin attenuates emotional impairment and blocks stress-induced reinstatement of morphine-seeking in morphine abstinent mice. Neuropsychopharmacology, 2014; 39, 855-65. 3. Zanos, P., Wright, R.S., Georgiou, P., Yoo, J.H., Hourani, S., Ledent, C., Winsky-Sommerer, R., Kitchen, I., Bailey, A. Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism. Pharmacology, Biochemistry and Behavior, 2014; 119, 72-9. 4. Chao, M., Fragou, D., Zanos, P., Hu, C., Bailey, A., Kouidou, S., Kovatsi, L. Epigenetically modified nucleotides in chronic heroin and cocaine treated mice. Toxicology letters, 2014; 229, 451-7. 5. Zanos, P., Georgiou, P., Hourani, S., Kitchen, I., Winsky-Sommerer, R., Bailey, A. Emotional impairement and persistent up-regulation of mGlu5 receptor following morphine abstinence: implications an mGlu5-MOPr interaction. International Journal of Neuropsychopharmacology, 2015; 19, 1-10. 6. Georgiou, P., Zanos, P., Ehteramyan, M., Hourani, S., Kitchen, I., Maldonado, R., Bailey, A. Differential regulation of mGlu5R and MOPr by priming- and cue-induced reinstatement of cocaine- seeking in mice. Addiction Biology, 2015; 20, 902-12. 7. Zanos, P., Georgiou, P., Metaxas, A., Kitchen, I., Winsky-Sommerer, R., Bailey, A. Region-specific up-regulation of oxytocin receptor binding in the brain of mice following chronic nicotine administration. Neuroscience Letters, 2015; 600, 33-37. 8. Zanos, P., Bhat, S., Smith, R., Terrillion, C., Tonelli, L., Gould, T. Sex-dependent modulation of sex-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav1.2). European Journal of Neuroscience, 2015; 42, 2499-507. 9. Georgiou, P., Zanos, P., Hourani, S., Kitchen, I., Bailey, A. The oxytocin analogue carbetocin prevents priming-induced reinstatement of morphine-seeking: involvement of the dopaminergic, noradrenergic and MOPr systems. European Journal of Neuropsychopharmacology, 2015; 12, 2459-2464. 10. Wright, R.S.*, Zanos, P.*, Yoo, J.H., Winsky-Sommerer, R., Hourani, S., Kitchen, I., Bailey, A. A critical role of striatal A2AR-mGlu5R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine. Addiction Biology, 2015; 4, 811-825. *Equal contribution. 11. Zanos, P., Piantadosi, S., Wu, HQ., Pribut, H., Dell, M., Can, A., Snodgrass, H.R., Zarate, C., Schwarcz, R., Gould, T. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. JPET, 2015; 355, 76-85. 12. Georgiou, P., Zanos, P., Garcia-Carmona, J.A., Hourani, S., Kitchen, I., Laorden, M.L., Bailey, A. Methamphetamine withdrawal induces an anxiogenic-like phenotype and brain region-specific alterations of the oxytocin and mu-opioid receptors in mice. Neuropharmacology, 2016 105, 520- 532. 13. Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G., Alkondon, M., Yuan, P., Pribut, H., Singh, N., Dossou, K., Fang, Y., Huang, XP., Mayo, C., Wainer, I., Albuquerque, E., Thompson, S.M., Thomas, C., Zarate Jr, C., Gould, T.D. 2016. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 2016; 533, 481-486. 14. Georgiou, P., Zanos, P., Hourani, S., Kitchen, I., Bailey, A. Cocaine abstinence induces emotional impairment and brain region-specific upregulation of the oxytocin receptor binding. European Journal of Neuroscience, 2016; 44, 2446-2454. 15. Can, A.*, Zanos, P.*, Moaddel, R., Huang, XP., Kang, H.J., Dossou, SS.D., Wainer, I.W., Cheer, J.F., Frost, D.O., Roth, BL., Gould, T.D. Effects of ketamine on electrically-evoked accumbal dopamine release and activity at dopamine receptors and transporters. JPET, 2016; 359, 159-170. * Equal contribution. 16. Zanos, P., Moaddel, R., Morris, P., Albuquerque, E., Wainer, I., Thompson, S., Thomas, C., Zarate Jr, C., Gould, T.D. Antidepressant actions of ketamine versus Hydroxynorketamine. Biological Psychiatry, 2016; 81, 69-71. 17. Gould, T.D., Zanos, P., Zarate Jr, C. Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology, 2016; 42, 368-369. 18. Gould, T.D., Georgiou, P., Brenner, L.A., Brundin, L., Can, A., Courtet, P., Donaldson, Z.R., Dwivedi, Y., Guillaume, S., Gottesman, I.I., Kanekar, S., Lowry, C.A., Renshaw, P.F., Rujescu, D., Smith, E.G., Turecki, G., Zanos, P., Zarate Jr, C., Zunszain, P.A., Postolache, T.T. Animal models to improve our understanding and treatment of suicidal behavior. Translational Psychiatry. 2017; 7, 1-22. 19. Martynhak, B., Hogben, A., Zanos, P., Georgiou, P., Andreatini, R., Kitchen, I., Archer, S., von Schantz, M., Bailey, A., van der Veen, D. Altered circadian response to night-time light exposure of PERIOD3 null mice associates with early onset of a depressive-like phenotype. Scientific Reports, 2017; 7:40399, doi: 10.1038/srep40399. 20. Zanos, P., Georgiou, P., Weber, C., Robinson, F., Kouimtsidis, C., Niforooshan, R., Bailey, A. Oxytocin and opioid addiction revisited: Old drug, new applications. British Journal of Pharmacology, 2017; doi: 10.1111/bph.13757. 21. Zanos, P., Nelson, M.E, Krimmel, S.R., Highland, J.N., Georgiou, P., Gould, T.D., Thompson, S.,M. A negative allosteric modulator for alpha5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro, 2017; doi:10.1523/ENEURO.0285-16.2017. 22. Zanos, P., Moaddel, R., Morris, P., Georgiou, P., Fischell, J., Elmer, G., Alkondon, M., Yuan, P., Pribut, H., Singh, N., Dossou, K., Fang, Y., Huang, XP., Mayo, C., Albuquerque, E., Thompson, S., Thomas, C., Zarate Jr, C., Gould, T.D. BCA: Effects of a ketamine metabolite on synaptic NMDAR function. Nature, 2017; 546, E4-E5. 23. Georgiou, P., Zanos, P., Bhat S., McCarthy, P., Merchenthaler, I., Tracy, J.K., Gould, T.D. Dopamine and stress system modulation of sex differences in decision-making. Neuropsychopharmacology, 2017; 43, 313-324. 24. Morris, P.J., Moaddel R., Zanos, P., Moore C.E., Gould T.D., Zarate C.A. Jr, Thomas, C.J. Synthesis and NMDA receptor activity of ketamine metabolites. Organic letters, 2017; 19, 4572- 4575. 25. Garcia-Carmona, J.A., Georgiou, P., Zanos, P., Bailey, A., Laorden, M.L. Methamphetamine withdrawal induces activation of CRF neurons in the brain stress system in parallel with an increased activity of cardiac sympathetic pathways. Naunym-Schmiedeberg’s Archives of Pharmacology, 2017; 391, 1-12. 26. Zanos, P., Gould, T.D. Intracellular signaling pathways involved in (S)- and (R)-ketamine antidepressant actions. Biological Psychiatry, 2017; 83, 2-4. 27. Keyworth, H., Georgiou, P., Zanos, P., Veloso Rueda A., Chen Y., Kitchen I., Camarini R., Cropley M., Alexis Bailey A. Wheel running during chronic nicotine exposure is protective against mecamylamine-precipitated withdrawal and up-regulates hippocampal α7 nACh receptors in mice. British Journal of Pharmacology, 2018; 175, 1928-1943. 28. Brown, P.L.*, Zanos, P.*, Wang, L., Mayo C.L., Elmer, G.I., Gould, T.D., Shepard, P.C. Isoflurane but not halothane prevents and reverses helpless behavior: a role for burst suppression? International Journal of Neuropsychopharmacology, 2018; In press. doi: 10.1093/ijnp/pyy029. *Equal contribution 29. Zanos, P., Duman, R.S., Thompson, S.M., Zarate Jr, C., Gould, T.D. Convergent mechanisms underlying rapid antidepressant action. CNS Drugs, 2018; 32, 197-227. 30. Zanos, P., Gould, T.D. Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 2018; 23, 811-817. 31. Zanos, P., Moaddel, R., Morris, P.J., Riggs, L.M., Highland, J.N., Georgiou, P., Pereira, E.F.R., Albuquerque, E.X., Thomas, C., Zarate Jr, C., Gould, T.D. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews, 2018; 70, 621- 660. 32. Rae, M., Zanos, P., Georgiou, P., Chivers, P., Bailey, A., Camarini, R. Paradoxical enhancement of alcohol rewarding properties by environmental enrichment: a role of the oxytocinergic system. Neuropharmacology, 2018; In press. doi: 10.1016/j.neuropharm.2018.06.013. 33. Zanos, P., Keyworth, H., Georgiou, P., Kitchen, I., Zimmer, A., Bailey, A. 2018. Chronic nicotine administration restores brain region specific upregulation of oxytocin receptor binding levels in a G72 mouse model of schizophrenia. European Journal of Neuroscience. In press. doi: 10.1111/ejn.14155. 34. Lumsden, E. *, Troppoli, T.A.*, Myers, S.J., Zanos, P., Aracava, Y., Kehr, J., Moaddel, R., Kim, S., Wang, F-H., Schmidt, S., Jenne, C.E., Yuan, P., Morris, P.J., Zarate, Jr, C.A., Thomas, C. J., Traynelis, S.F., Pereira, E. F.R., Thompson, S.M., Albuquerque, E.X., Gould, T.D. 2019. NMDA receptor function and the antidepressant effects of the ketamine metabolite (2R,6R)- hydroxynorketamine. PNAS, 2019; 116,5160-5169. * Equal contribution 35. Georgiou, P., Zanos, P., Jenne, E.C., Gould, T.D. Sex-specific differential regulation of behavioral responses to stress by estrogen receptors. Frontiers in Psychiatry, 2019; 10:81. 36. Zanos, P., Highland, J.N., Georgiou, P., Jenne, C.E., Morris, P.J., Moaddel, R., Xye, J.K., Zarate Jr, C., Gould, T.D. (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. PNAS, 2019; 116,6441-6450. 37. Zanos, P., Highland, J.N., Xin, L., Georgiou, P., Stewart, B.W., Moaddel, R., Xye, J.K., Gould, T.D. (R)-ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anesthetic doses. British Journal of Pharmacology, 2019; 176 2573-2592. 38. Rao, X., Asico L.D., Zanos, P., Mahabeleshwar, G.H., Gangwar, R.S., Xia, C., Duan, L., Cisse, YM., Rengasamy, P., Jose, P.A., Gould, T.D., Nelson, R., Biswal, S., Chen, LC., Zhong, J., Rajagopalan, S. Alpha2B-adrenergic receptor overexpression in the brain potentiates air pollution-induced behavior and blood pressure changes. Toxicological sciences, 2019, 169, 95-107. 39. Highland, J.N., Zanos, P., Georgiou, P., Gould, T.D. Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology. In Press, doi: 10.1038/s41386-019-0380-1. 40. Riggs, L., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E.X., Perreira, E.F.R., Thompson, S.M., Gould, T.D. (2R,6R)-hydroxynorketamine acts presynaptically to rapidly and selectively enhance glutamatergic transmission at Schaffer collateral synapses. Neuropsychopharmacology. In Press, doi: 10.1038/s41386-019-0443-3. 41. Krimmel, S.R.*, Zanos, P.*, Georgiou, P., Colloca, L., Gould, T.D. Classical conditioning of antidepressant placebo effects in mice. Psychopharmacology. In press. * Equal ontribution.

Submitted or In-Revision Peer-reviewed journal articles

1. Zhang, Y., Zanos, P., Jackson, I., Zhang, X., Zhu, X., Gould, T.D., Vujaskovic, Z. Adrenergic epithelial-mesenchymal transition in psychological stress enhanced lung tumor growth and radioresistance (In revision). 2. Georgiou, P., Zanos, P., Hourani, S., Kitchen, I., Bailey, A. Alcohol administration and withdrawal induces brain region-specific alterations on the oxytocin and MOPr binding (In revision)

Proffered Communications

1. British Pharmacological Society (BPS) winter meeting, London, U.K. 2011. ‘Persistent brain region- specific up-regulation of the V1a receptor following chronic cocaine and morphine administration and withdrawal in mice’. 2. University Global Partnership Network Workshop: Genes and Behaviour, Guildford, Surrey, U.K. 2012. ‘Carbetocin reverses emotional impairment during prolonged morphine withdrawal’. 3. British Pharmacological Society (BPS) winter meeting, London, U.K. 2012. ‘The oxytocin analogue carbetocin reverses impaired emotional-like behavior during prolonged abstinence from chronic morphine treatment’. 4. University of Maryland, Baltimore, Program in Neuroscience, Annual Retreat, Baltimore, U.S. 2014. ‘4-Cl-kynurenine, a prodrug of a selective glycineB NMDA receptor antagonist, induced rapid and sustained antidepressant effects without ketamine-related side effects’. 5. School of Biological Psychatry, Annual meeting 2017, San Diego, California. ‘Ketamine exerts NMDAR inhibition-independent antidepressant actions via its hydroxynorketamine metabolites’. 6. Baltimore Brain Series, NIDA 2017, Baltimore, USA. ‘NMDAR inhibition-independent antidepressant actions of ketamine’s metabolites’. 7. European College of Neuropsychopharmacology, Congress 2017, Paris, France. ‘Ketamine exerts NMDAR inhibition-independent antiderepssant actions via its hydroxynorketamine metabolites’. 8. International Behavioral Neuroscience Society, Conference 2018, Florida, U.S. ‘Ketamine and hydroxynorketamines: NMDAR inhibition independent mechanisms underlying rapid acting antidepressant efficacy’. Symposium chair. 9. Society for Neuroscience, 2018, San Diego, U.S. ‘(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions’. 10. American College of Neuropsychopharmacology – ACNP, Hollywood, FL, U.S., 2018. ‘Mechanisms underlying antidepressant actions of ketamine’s (2R,6R)-hydroxynorketamine metabolite.